NASDAQ:ENTA - Enanta Pharmaceuticals, Inc.
$82.49
 $0.49
+0.60%
4:00PM EDT
2019-07-22
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305 and EDP-938. Paritaprevir The Company's Paritaprevir product is an NS3/4A protease inhibitor. The Company's product, Paritaprevir, is a DAA in VIEKIRA PAK and the other treatment regimens. ABT-493 The Company is developing its second protease inhibitor, glecaprevir (ABT-493). AbbVie has co-formulated ABT-493 with its second NS5A inhibitor, pibrentasvir (ABT-530), and is developing them as its next combination, which is referred to as G/P, for HCV treatment. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ENTA     avg for
industry  
  avg for
sector  
42 stocks weight:  52. 06   217. 37   399. 45  
42 stocks rank:  2. 37 K 1. 27 K 716. 99  
# analyst opinions:  7. 00   13. 21   13. 71  
mean recommendation:  2. 40   2. 10   2. 04  

quick ratio:  20. 00   5. 49   1. 88  
current ratio:  20. 68   5. 87   2. 36  

target price low:  82. 00   83. 44   114. 90  
target price avg:  109. 00   106. 20   137. 90  
target price high:  130. 00   132. 30   158. 97  
1-yr high:  118. 67   111. 86   142. 57  
last close:  82. 00   86. 79   125. 44  
50-day avg:  88. 40   86. 68   122. 63  
200-day avg:  85. 36   89. 22   121. 38  
1-yr low:  65. 41   69. 78   100. 51  
volume:  196. 56 K 2. 62 M 3. 43 M
50-day avg volume:  185. 07 K 3. 20 M 4. 16 M
200-day avg volume:  237. 20 K 2. 99 M 4. 75 M

1-day return:  -1. 71 % -1. 30 % -0. 99 %
this week return:  -3. 34 % 0. 45 % -0. 20 %
12-wk return:  -8. 28 % 0. 94 % 4. 84 %
52-wk return:  -27. 83 % -1. 30 % 10. 55 %

enterprise value (EV):  1. 24 B 45. 10 B 122. 38 B
market cap:  1. 61 B 38. 96 B 108. 40 B
EBITDA:  86. 44 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  14. 40   5. 38   11. 93  
enterprise/revenue (EV/R):  5. 32   57. 92   10. 21  
total revenue:  233. 98 M 9. 91 B 39. 98 B
total debt:  1. 88 M 10. 90 B 17. 48 B
debt/equity:  0. 43   57. 18   120. 05  
net income (common):  77. 86 M 2. 07 B 4. 05 B

shares outstanding:  19. 67 M 538. 09 M 1. 24 B
shares:  15. 92 M 548. 00 M 1. 22 B
shares short:  1. 83 M 10. 98 M 11. 87 M
shares short prior month:  2. 18 M 9. 32 M 12. 05 M
short ratio:  8. 68   5. 60   3. 34  
short % of float:  11. 45 % 6. 48 % 2. 64 %
total cash/share:  18. 82   10. 98   9. 19  
total cash:  370. 16 M 5. 93 B 6. 10 B
free cash flow:  67. 79 M 2. 92 B 4. 55 B
operating cash flow:  92. 73 M 3. 80 B 5. 78 B

book value:  22. 18   13. 35   27. 45  
price/book:  3. 70   4. 60   8. 78  
gross profits:  206. 62 M 7. 44 B 36. 13 B
operating margins:  35. 75 % -308. 40 % -28. 55 %
EBITDA margins:  36. 94 % 13. 17 % 23. 38 %
profit margins:  33. 28 % 10. 44 % 14. 18 %
gross margins:  100. 00 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  3. 70   2. 10   4. 23  
forward EPS:  -0. 54   3. 45   7. 10  
P/E:  22. 15   1. 90   32. 10  
forward P/E:  -151. 85   6. 46   15. 47  
PE/G:  -0. 91   0. 70   -0. 54  
growth:  -24. 25 % 265. 63 % 79. 11 %
earnings high:  0. 60   0. 89   1. 68  
earnings avg:  0. 20   0. 70   1. 57  
earnings low:  0. 01   0. 46   1. 46  
revenue high:  58. 10 M 2. 57 B 11. 07 B
revenue avg:  49. 40 M 2. 51 B 10. 91 B
revenue low:  44. 13 M 2. 45 B 10. 73 B
earnings growth:  -67. 20 % 12. 05 % 30. 99 %
1-qtr earnings growth:  -67. 00 % 9. 70 % 30. 42 %
return on assets:  12. 81 % -2. 34 % 5. 28 %
return on equity:  20. 23 % -90. 08 % 133. 53 %
revenue growth:  -10. 00 % 265. 25 % 73. 68 %
revenue/share:  12. 05   12. 72   60. 04  

beta (1yr vs S&P500):  1. 48   1. 27   0. 91  
sharpe (1yr):  -0. 53   0. 16   0. 77  

held % insiders:  24. 93 % 6. 06 % 3. 29 %
held % institutions:  87. 35 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : ENTA
.    145.487 =       145.487 :: --> INITIAL WEIGHT <--
.    + 3.702 =       149.189 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.866 =       427.621 :: P/E factor
.    x 1.023 =       437.414 :: PE/G factor
.    x 1.676 =       733.055 :: beta factor
.    x 0.828 =       606.669 :: sharpe factor
.    x 3.689 =      2238.127 :: current ratio factor
.    x 1.026 =      2296.276 :: quick ratio factor
.    x 1.056 =      2424.945 :: short ratio factor
.    x 1.271 =      3081.006 :: return on assets factor
.    x 1.368 =      4215.931 :: return on equity factor
.    x 0.756 =      3186.437 :: earnings growth factor
.    x 1.092 =      3479.037 :: EV/R factor
.    x 1.044 =      3632.063 :: price-to-book factor
.    x 1.145 =      4158.602 :: EBITDA factor
.    x 1.294 =      5382.872 :: EBITDA vs industry factor
.    x 5.776 =     31090.436 :: debt-to-revenue factor
.    x 1.004 =     31207.115 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =     66183.832 :: sector+industry 1-year gains factor
.    x 1.009 =     66807.817 :: industry 12-weeks return factor
.    x 1.308 =     87377.181 :: industry 2-weeks return factor
.    x 0.926 =     80906.663 :: company one-year gains+dividend factor
.    x 0.982 =     79466.678 :: company 13 weeks' performance factor
.    x 1.036 =     82294.109 :: 50-day avg > 200-day avg
.    x 0.979 =     80556.197 :: "drift" penalty 1 days ago
.    / 1.918 =     42005.482 :: overall "drift" factor
.    x 0.815 =     34226.597 :: largest single-day jump factor
.        x 1 =     34226.597 :: volatility factor
.        x 1 =     34226.597 :: 42-day volatility factor
.    x 1.781 =     60969.465 :: notable returns + performance factor
.    x 3.278 =    199837.971 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.292 =     58272.752 :: forward EPS factor
.    x 0.743 =     43272.265 :: forward P/E factor
.    x 1.185 =     51265.193 :: industry recommendation factor
.    x 1.801 =     92348.072 :: company recommendation factor
.    x 1.003 =      92603.45 :: factor historical industry gain for week 29
.      x 1.0 =      92603.45 :: target low factor
.    x 1.191 =    110315.991 :: target mean factor
.    x 1.032 =     113860.87 :: target high factor
.   x 10.226 =   1164357.533 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        32.849 :: reduced for readability
.   + 18.913 =        51.761 :: add/subtract for investor sentiment
.    + 0.294 =        52.056 :: earnings report in 16 days
.                               --> FINAL WEIGHT <--
.                     52.056 :: FINAL WEIGHT for NASDAQ:ENTA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org